Harmony Biosciences Holdings Inc. (HRMY) Physician Survey Indicates a Widening Footprint for Wakix - Piper Sandler

February 2, 2022 8:59 AM EST Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $57.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login